This blend combines CJC-1295, a long-acting growth hormone-releasing hormone (GHRH) analog, with GHRP-2, a rapidly acting growth hormone-releasing peptide. It is typically administered via subcutaneous injection to stimulate growth hormone release. Dosing usually ranges from 150-300 mcg daily, with protocols often involving a gradual increase in dosage over several weeks.
- Combines a long-acting GHRH with a rapid-acting GHRP.
- Administered via subcutaneous injection, typically once daily.
- Requires reconstitution with bacteriostatic water.
- Dosage is often adjusted gradually over the cycle.
Reconstitution
Vial strength
10 mg
Bacteriostatic water
3 mL
Concentration
3.33 mg/mL
1 unit = 0.01 mL = 33.3 mcg on a U-100 insulin syringe
- 1Draw 3.0 mL of bacteriostatic water using a sterile syringe.
- 2Carefully inject the water into the peptide vial, directing it down the vial wall to prevent foaming.
- 3Gently swirl or roll the vial until the powder completely dissolves; avoid shaking.
- 4Label the reconstituted vial with the date and store it in the refrigerator at 2–8 °C (35.6–46.4 °F), protected from light.
Dosing schedule
| Phase | Dose | On a U-100 syringe |
|---|---|---|
| Weeks 1-2 | 150 mcg | 4.5 units (0.045 mL) |
| Weeks 3-12 | 300 mcg | 9 units (0.09 mL) |
Protocol detail
| Start | Begin with 100–150 mcg daily for the first 1–2 weeks, allowing the body to adjust. |
|---|---|
| Target | Increase the dose to 250–300 mcg daily for Weeks 3–12. |
| Frequency | Administer once per day via subcutaneous injection, ideally in the evening or before bedtime. |
| Cycle Length | Typical cycle duration is 8–12 weeks, with the possibility of extending to 16 weeks. |
| Timing | Inject on an empty stomach and regularly rotate injection sites. |
Overview at a glance
| Goal | To support enhanced growth hormone pulsatility and sustained IGF-1 elevation throughout the research period. |
|---|---|
| Schedule | Daily subcutaneous injections for 8–12 weeks, with an option to extend to 16 weeks. |
| Dose Range | 100–300 mcg daily (total blend), starting with a lower dose and gradually increasing. |
| Reconstitution | Use 3.0 mL of bacteriostatic water per 10 mg vial, resulting in approximately 3.33 mg/mL concentration, for precise unit measurements. |
| Storage | Lyophilized peptide can be refrigerated or frozen. Reconstituted solution must be refrigerated and used promptly. Avoid multiple freeze-thaw cycles. |
How it works
CJC-1295 is a modified GHRH analog designed for an extended half-life, promoting sustained elevation of growth hormone (GH) and insulin-like growth factor 1 (IGF-1) for several days after a single dose. GHRP-2, conversely, is a ghrelin mimetic that rapidly stimulates acute, pulsatile GH release, peaking shortly after administration. When combined, these peptides work synergistically: CJC-1295 provides a foundation of elevated GH and IGF-1, while GHRP-2 adds sharp, intense GH pulses. This combination aims to maximize the body's natural GH production and its downstream effects.
Reported effects
- Sustained elevation of GH and IGF-1 levels
- Enhanced muscle growth and recovery
- Improved body composition
- Potential anti-aging effects
Reported side effects
- Transient increase in appetite (due to GHRP-2)
- Mild, temporary elevations in ACTH, cortisol, and prolactin
- Occasional facial flushing or lightheadedness (with higher CJC-1295 doses)
- Minor injection site reactions (redness, itching)
Storage
Lyophilised (unmixed)
Refrigerate at 2–8 °C (35.6–46.4 °F) or freeze at −20 °C (−4 °F) for long-term storage.
After reconstitution
Refrigerate at 2–8 °C (35.6–46.4 °F) and use within 2–4 weeks; protect from light.
Supplies
| Peptide vials | Approximately 2-4 vials of CJC-1295 + GHRP-2 (10 mg each) for an 8-16 week protocol. |
|---|---|
| Insulin Syringes (U-100) | Around 56-112 syringes for an 8-16 week daily protocol (one per day). |
| Bacteriostatic Water | One to two 10 mL bottles needed, as approximately 3.0 mL is used per vial. |
| Alcohol Swabs | Roughly 112-224 swabs for an 8-16 week protocol (two per day: one for vial, one for skin). |
Important notes
- Always use a new, sterile insulin syringe for each injection and dispose of it properly in a sharps container.
- Rotate subcutaneous injection sites (e.g., abdomen, thighs, upper arms) to prevent irritation.
- Inject on an empty stomach, as food intake, especially carbohydrates, can diminish GHRP-2's effect.
- Document daily doses and injection sites for consistency.
- No post-cycle therapy is generally required, as hormone levels typically return to baseline.
Frequently asked questions
What is the difference between CJC-1295 and GHRP-2, and why are they blended?
CJC-1295 is a long-acting GHRH analog that increases baseline GH and IGF-1 levels for an extended period. GHRP-2 is a rapid-acting peptide that causes quick, pulsatile spikes in GH. They are blended to leverage both benefits: CJC-1295 provides sustained elevation while GHRP-2 adds powerful, acute GH pulses, optimizing the overall growth hormone response.
Can I split the daily dose into two injections?
Yes, some advanced protocols suggest splitting the daily dose into two administrations, typically once in the morning (fasted) and once in the evening (before bed). This can potentially enhance GH pulsatility. If doing so, ensure doses are spaced at least 3-8 hours apart to avoid overlapping GH pulses.
How long does it take to see results?
The time to see results can vary. Given the sustained nature of CJC-1295 and the pulsatile action of GHRP-2, users may begin to notice benefits like improved recovery, better sleep, and subtle changes in body composition within a few weeks, with more significant effects typically observed over an 8-12 week cycle.
Is post-cycle therapy (PCT) necessary after using CJC-1295 + GHRP-2?
No, post-cycle therapy is generally not required for this peptide blend. Once administration ceases, the body's natural growth hormone and IGF-1 levels are expected to gradually return to their baseline without intervention, as the peptides stimulate endogenous production rather than replacing it.
Educational reference only. These figures summarise how CJC-1295 + GHRP-2 is commonly described in research literature and supplier documentation, including the CJC-1295 + GHRP-2 listing at peptidesuk4u.co.uk. They are not a prescription, not medical advice, and not a recommendation to self-administer anything.
Related protocols
Tesamorelin + Ipamorelin (10 mg Blend)
Synergistic blend for enhanced growth hormone release and fat reduction.
CJC-1295 DAC (2 mg Vial)
Long-acting GHRH analog for sustained growth hormone release.
CJC-1295 DAC + Ipamorelin Stack (CJC-1295 (2 mg) + Ipamorelin (5 mg))
Amplify growth hormone production with this synergistic peptide stack.
Ipamorelin (5 mg Vial)
Selective growth hormone secretagogue for lean mass, recovery, and fat metabolism.